Afm24 clinical

Author: pgnt

August undefined, 2024

WebNov 10, 2024 · In AFM24-101, the monotherapy phase 1/2a clinical trial, a weekly dose of 480 mg has been identified as the recommended phase 2 dose based on a comprehensive review of safety, pharmacokinetic and pharmacodynamic data, including exposure and NK cell CD16A receptor occupancy. WebJun 2, 2024 · AFM24 is a novel ICE that targets epidermal growth factor receptor (EGFR), which is often overexpressed in solid tumors. The Phase 1 study of AFM24 monotherapy showed patients had a manageable safety profile, and SNK01 monotherapy has also shown to be well-tolerated in patients with rapidly progressive solid tumors.

The Combination of CD16A/EGFR Innate Cell Engager, …

WebSep 4, 2024 · Affimed is evaluating AFM24 as a monotherapy (AFM24-101) for patients with advanced EGFR-expressing solid malignancies whose disease has progressed after … WebFeb 26, 2024 · AFM24 is a form of immunotherapy that acts as a bridge between innate immune cells — the first line of defense against threats — and cancer cells. Called an innate cell engager (ICE), the treatment works by binding to proteins on both cell types, bringing immune cells closer to the tumor site for more effective killing. herec mcconaughey

Clinical Trial: NCT04259450 - My Cancer Genome

WebMar 17, 2016 · afm24 On Sunday, April 17, "Highly cytotoxic EGFR/CD16A TandAbs specifically recruit NK cells to potently kill various types of solid tumors" (Abstract #593) will be available in a poster session. WebJul 30, 2024 · To advance AFM24 into clinical development, the safety of . AFM24 in cynomolgus monkeys was determined in a 28-day . toxicity study with repeated intravenous infusion (2-hour infu- WebApr 12, 2024 · A new immunotherapy, AFM24, has reignited hopes for millions of cancer patients across the world. In a trial conducted by the Institute of Cancer Research (ICR) at the Royal Marsden NHS... matthew henry women came from a man\u0027s rib

Abstract 5659: AFM24, a bispecific EGFR/CD16A …

Affimed N : Presentation MarketScreener

WebAFM24 was highly potent and effective for antibody-dependent cell-mediated cytotoxicity via NK cells, and also mediated antibody-dependent cellular phagocytosis via macrophages … Web• Safety and tolerability of AFM24 in combination with SNK01 cells • Preliminary efficacy; assessed by evaluating progression-free survival (PFS) and overall survival (OS) (as per RECIST v1.1) Phase 2a • Safety and tolerability of AFM24 in combination with SNK01 cells • PFS, OS, duration of response clinical benefit rate matthew henson 10 factsWebSep 4, 2024 · AFM24 is a tetravalent, bispecific innate cell engager (ICE ®) that activates the innate immune system by binding to CD16A on innate immune cells and EGFR, a protein widely expressed on solid tumors, to kill cancer cells. herec milan ligač

"WebApr 8, 2024 · AFM24 is a tetravalent, bispecific innate cell engager (ICE®) that activates the innate immune system by binding to CD16A on innate immune cells and EGFR, a protein widely expressed on solid tumors, to kill cancer cells. " - Afm24 clinical

Afm24 clinical

The combination of CD16A/EGFR innate cell engager, AFM24, …

WebApr 12, 2024 · AFM24 induces NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against EGFR-expressing tumor cells even in the presence of competing IgG and can induce potent cell killing in... WebFeb 6, 2024 · AFM24 is a tetravalent bispecific (anti-human EGFR x anti-human CD16A) innate immune cell engaging recombinant antibody construct being developed to target …

Did you know?

WebAssessing Clinical Symptom Patterns Several types of scales have been developed to evalu-ate clinical problems. There are three types of scales that address problems in … WebJun 2, 2024 · AFM24 is a novel ICE that targets epidermal growth factor receptor (EGFR), which is often overexpressed in solid tumors. The Phase 1 study of AFM24 monotherapy …

WebMay 26, 2024 · AFM24 utilizes the patient’s innate immunity to redirect and activate immune cells, overcoming resistance to current therapies. The primary mode of action of AFM24 … WebA Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers Erkrankung

WebAFM24, an EGFR-directed ICE®(innate cell engager) molecule, represents a distinctive mechanism that engages innate immune cells by recruiting NK cells and macrophages to the site of the tumor for effective and efficient tumor-cell killing.8The differentiated MOA does not rely on the EGFR signaling pathway for tumor killing but instead uses EGFR … WebJun 2, 2024 · AFM24 is a first in class, tetravalent, bispecific, novel ICE targeting EGFR. By binding to EGFR on tumor cells and CD16A on innate immune cells, AFM24 may utilize …

WebThe Institute of Cancer Research in London is the leading UK center of the trial investigating our innate cell engager AFM24 as a monotherapy and has shared its latest update at AACR. Find out ... herec matonohaWebSep 4, 2024 · Affimed is evaluating AFM24 as a monotherapy (AFM24-101) for patients with advanced EGFR-expressing solid malignancies whose disease has progressed after … herec michal kocourekWebAFM24 & SNK01 THERAPY • AFM24 is a tetravalent bispecific innate cell engager (ICE®) derived from the redirected optimized cell killing (ROCK®) antibody platform • AFM24 … matthew henson and robert pearyWebFeb 3, 2024 · Heidelberg, Germany, February 3, 2024 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has entered into a clinical research collaboration with Roche to explore the combination of Affimed’s innate cell engager … herec lubo romanWebJun 29, 2024 · Affimed continues to enroll patients in all three AFM24 clinical trials and is planning to present data in the second half of this year. This should reveal the efficacy of the company's three ... here cmdWebApr 10, 2024 · Clinical success story (based on AFM13, AFM24): Superior safety profile compared to other treatment options; Utility across multiple indications; Well suited for combinations: Synergy with NK cells; Synergy with CPIs; 5 Attachments. Original Link Original Document Permalink ... matthew henson apartments phoenixWebJan 7, 2024 · AFM24-101, a Phase 1/ 2 a clinical trial of AFM24, the EGFR/CD16A targeted ICE ® for treatment of patients with EGFR-expressing solid tumors,... Heidelberg, Germany, January 7, 2024– Affimed N ... matthew henson and peary